References

---

1	Rombauts B. "Farmaceutische Microbiologie (met inbegrip van de farmaceutische technologie van steriele geneesmiddelen)." Cursus 1ste graad apotheker VUB 1997;11:14-16.
2	Franchini G, Bosch ML. "Genetic relatedness of the human immunodeficiency viruses type 1 and 2 (HIV-1, HIV-2) and the simian immunodeficiency virus (SIV)". Ann N Y Acad Sci 1989;554:81-7.
3	Huet T, Cheyneir R, Meyerhans A et al. "Genetic organization of a chimpanzee lentivirus related to HIV-1." Nature 1990; 345:356-359.
4	"Anonymous survey for simian immunodeficiency virus (SIV) seropositivity in SIV laboratory researchers." United States, 1992. MMWR Morb Mortal Wkly Rep 1992;41:814-5.
5	Zhu, Tuofu, Bette Korber, Andre J Nahinias. "An African HIV-1 Sequence from 1959 and Implications for the Origin of the Epidemic." Nature, 1998; 391: 594.
6	Alvin E. Friedman-Kien. "Color Altas of AIDS" W.B. Saunders Company, 1989 (2-4)
7	Centers for Disease Control. "1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults." MMWR 1992;41:1-19.
8	Cohen P.T. "Understanding the HIV disease: hallmarks, clinical spectrum, what we need to know." The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/04over/index.html, June 1998.
9	Centers for Disease Control: Current trends: Classification system for human T lymphotropic virus type III/lymphadenopathy assiociated virus infections. MMWR 1986;35:334-339
10	Osmond Dennis H. "Classification, Staging and surveillance of HIV disease" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/01class, 1998
11	Osmond Dennis H. "Epidemiology of Disease Progression in HIV Infection: Incubation Period, AIDS Survival Time, Laboratory Markers, and Cofactors."  The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/01prog/index.html, 1998.
12	Phillips AN, Lee CA, Elford J, et al. "Serial CD4 lymphocyte counts and development of AIDS." Lancet 1991;337:389-392.
13	Balotta C, Bagnarelli P, Riva C, et al. "Comparable biological and molecular determinants in HIV type 1-infected long-term nonprogressors and recently infected individuals." AIDS Res Hum Retroviruses 1997;13:337-341.
14	Bacchetti P, Moss AR. "Incubation period of AIDS in San Francisco." Nature 1989;338:251-253.
15	Rosenberg PS, Goedert JJ, Biggar RJ. "Effect of age at seroconversion on the natural AIDS incubation distribution. Multicenter Hemophilia Cohort Study and the International Registry of Seroconverters." AIDS 1994;8:803-810.
16	Gail MH, Tan WY, Pee D, et al. "Survival after AIDS diagnosis in a cohort of hemophilia patients. Multicenter Hemophilia Cohort Study." J Acquir Immune Defic Syndr Hum Retrovirol 1997;15:363-369.
17	Longini Jr IM, Clark WS, Gardner LI, et al. "The dynamics of CD4+ T-lymphocyte decline in HIV-infected individuals: A Markov modeling approach." J Acquir Immune Defic Syndr Hum Retrovirol 1991;4:1141-1147.
18	Osmond Dennis H. "Sexual Transmission of HIV " The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/01sextx/index.html, 1998.
19	Mann J, Chin J, Piot P, et al. "The international epidemiology of AIDS." Sci Am 1988;259:82-89.
20	Donnelly C, Leisenring W, Kanki P, et al. "Comparison of transmission rates of HIV-1 and HIV-2 in a cohort of prostitutes in Senegal." Bull Math Biol 1993;55:731-743.
21	European, HIV SGoHTo. "Comparison of female to male and male to female transmission of HIV in 563 stable couples. European Study Group on Heterosexual Transmission of HIV." BMJ 1992;304:809-813.
22	Moss A, Osmond D, Bacchetti P, et al. "Risk factors for AIDS and HIV seropositivity in homosexual men." Am J Epidemiol 1987;125:35-47.
23	Padian N, Marquis L, Francis DP, et al. "Male-to-female transmission of human immunodeficiency virus." JAMA 1987;258:788-790.
24	Voelker R. "Global vaccines." JAMA 1997;278:460.
25	Anderson DJ, O'Brien TR, Politch JA, et al." Effects of disease stage and zidovudine therapy on the detection of human immunodeficiency virus type 1 in semen." JAMA 1992;267:2769-2774.
26	Musicco M, Lazzarin A, Nicolosi A, et al. "Antiretroviral treatment of men infected with human immunodeficiency virus type 1 reduces the incidence of heterosexual transmission. Italian Study Group on HIV Heterosexual Transmission." Arch Intern Med 1994;154:1971-1976.
27	Burack Jeffrey H., Bangsberg D. "Epidemiology and Transmission of HIV Among Injection Drug Users" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/01idu/index.html, may 1998.
28	Donegan Elizabeth "Transmission of HIV by Blood, Blood Products, Tissue Transplantation, and Artificial Insemination" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/01txbld/index.html, may 1997.
29	Donegan E, Lee H, Operskalski EA, et al. "Transfusion transmission of retroviruses: Human T-lymphotropic virus types I and II compared with human immunodeficiency virus type 1." Transfusion 1994;34:478-483.
30	Berkman SA, Groopman JE. "Transfusion associated AIDS." Transfus Med Rev 1988;2:18-28.
31	Simonds R.J. "HIV transmission by organ and tissue transplantation." AIDS 1993;7(Suppl 2):S35-S38.
32	Morbidity & Mortality Weekly Report Update. "Perinatally Acquired HIV/AIDS" United States, 1997;46(46):1086-1092.
33	Kline Mark K. "Prevention of HIV Vertical Transmission." The AIDS Reader 1996;6(1):5.
34	Schwartz J.S., Dans P.E., Kinosian B.P. "Human immunodeficiency virus test evaluation, performance and us"e. JAMA 1988;259:2574-2579.
35	Sax PE, Brodie. "Novel approaches to HIV antibody testing." AIDS Clinical Care, 1997;9:1-6.
36	Constantine N. "HIV Antibody Testing." The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/02abtest/index.html, February 1998.
37	Constantine N. "Tests to Detect HIV Antigen." The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/02agtest/index.html, February 1998.
38	Dailey P.J., Hayden D. "Viral Load Assays: Methodologies, Variables, and Interpretation." The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/02qrna/index.html , April 1998.
39	Young J.A.T. "The replication cycle of HIV-1" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/03lifcyc/index.html, February 1997.
40	Capon D.J., Ward R.H. "The CD4-gp120 interaction and AIDS pathogenesis". Annu Rev Immunol 1991;9:649-678.
41	Stein B.S., Gowda S.D., Lifson J.D., et al. "pH-independent HIV entry into CD4-positive T cells via virus envelope fusion to the plasma membrane." Cell 1987;49:659-668.
42	Katz R.A., Skalka A.M." Generation of diversity in retroviruses." Annu Rev Genetics 1990;24:409-445.
43	Lewis P., Hensel M. & Emerman M. "Human immunodeficiency virus infection of cells arrested in the cell cycle." EMBO J 1992; 11:3053-3058.
44	Bryant M., Ratner L. "Myristylation-dependent replication and assembly of human immunodeficiency virus 1." Proc Natl Acad Sci USA 1990;87:523-527.
45	Parent L.J., Bennett R.P., Craven RC.., et al. "Positionally independent and exchangeable late budding functions of the Rous sarcoma virus and human immunodeficiency virus Gag proteins." J Virol 1995;69:5455-5460.
46	Earl P.LL, Moss B., Doms R.W. "Folding, interaction with GRP78-BiP, assembly, and transport of the human immunodeficiency virus type 1 envelope protein." J Virol 1991;65:2047-2055.
47	Hope Thomas J., Trono D. "Structure, expression and regulation of the HIV-1 genome" The AIDS Knowledge Base http://hivinsite.ucsf.edu/akb/1997/03genome/index.html March 1998.
48	Gallay P., Swingler S., Song J., et al. "HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase." Cell 1995;83:569-576.
49	Lewis P., Hensel M., Emerman M. "Human immunodeficiency virus infection of cells arrested in the cell cycle." EMBO J 1992;11:3053-3058.
50	Thali M., Bukovsky A., Kondo E., et al. "Functional association of cyclophilin A with HIV-1 virions." Nature 1994;372:363-365.
51	Harrison G.P., Lever A.M. "The human immunodeficiency virus type 1 packaging signal and major splice donor region have a conserved stable secondary structure." J Virol 1992;66:4144-4153.
52	Poznansky M., Lever A., Bergeron L., et al. "Gene transfer into human lymphocytes by a defective human immunodeficiency virus type 1 vector." J Virol 1991;65:532-536.
53	Lapadat-Tapolsky M., De Rocquigny H., Van Gent D., et al. "Interactions between HIV-1 nucleocapsid protein and viral DNA may have important functions in the viral life cycle." Nucleic Acids Res 1993;21:831-839.
54	Ashorn P., McQuade T.J., Thaisrivongs S., et al. "An inhibitor of the protease blocks maturation of human and simian immunodeficiency viruses and spread of infection." Proc Natl Acad Sci USA 1990;87:7472-7476.
55	Bernstein H.B., Tucker S.P., Kar S.R., et. al. "Oligomerization of the hydrophobic heptad repeat of gp41." J Virol 1995;69:2745-2750.
56	Roy S., Delling U., Chen C.H., et al. "A bulge structure in HIV-1 TAR RNA is required for Tat binding and Tat-mediated trans-activation." Genes Dev 1990;4:1365.
57	Feinberg M.B., Baltimore D., Frankel A.D. "The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation." Proc Natl Acad Sci USA 1991;88:4045-4049.
58	Parada C.A. & Roeder R.G. "Enhanced processivity of RNA polymerase II triggered by Tat-induced phosphorylation of its carboxy-terminal domain." Nature 1996;384:375-378.
59	Garcia J.V. & Miller A.D. "Downregulation of cell surface CD4 by nef." Res Virol 1992;143:52-55.
60	Luria S., Chambers I., Berg P. "Expression of the type 1 human immunodeficiency virus Nef protein in T cells prevents antigen receptor-mediated induction of interleukin 2 mRNA." Proc Natl Acad Sci USA 1991;88:5326-5330.
61	Miller M.D., Warmerdam M.T., Gaston I., et al." The human immunodeficiency virus-1 nef gene product: A positive factorfor viral infection and replication in primary lymphocytes and macrophages." J Exp Med 1994;179:101-113.
62	Heinzinger N.K., Bukinsky M.I., Haggerty S.A., et al. "The Vpr protein of human immunodeficiency virus type 1 influences nuclear localization of viral nucleic acids in nondividing host cells." Proc Natl Acad Sci USA 1994;91:7311-7315.
63	Rogel M.E., Wu L.I., Emerman M. "The human immunodeficiency virus type 1 vpr gene prevents cell proliferation during chronic infection." J Virol1995;69:882-888.
64	Sato A., Igarashi H., Adachi A., et al. "Identification and localization of vpr gene product of human immunodeficiency virus type 1." Virus Genes 1990;4:303-312
65	Willey R.L., Maldarelli .F, Martin M.A., et al. "Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4." J Virol 1992;66(12):7193-7200.
66	Klimkait T., Strebel K., Hoggan M..A., et al. "The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release." J Virol 1990;64:621-629.
67	Schacker T.W., Hughes J.P., Shea T., et al." Biological and virologic characteristics of primary HIV infection." Ann Intern Med 1998;128:613-620.
68	Rosenberg E.S., Billingsley J.M., Caliendo A.M., et al. "Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia". Science 1997;278(5342):1447-1450.
69	Tindall B. & Cooper D.A. "Primary HIV infection: Host responses and intervention strategies." AIDS 1991;5:1-14.
70	Cohen O.J., Pantaleo G., Schwartzentruber D.J., et al. "Pathogenic insights from studies of lymphoid tissue from HIV-infected individuals." J Acquir Immune Defic Syndr Hum Retrovirol 1995;10(Suppl 1):S6-S14.
71	Mulligan K. & Schambelan M. "Wasting" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05wast/index.html, June 199.8
72	Greenspan D. "Oral manifestaions of HIV disease" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05oral/index.html, June 1998.
73	Feigal D.W., Katz M.H., Greenspan D., et al. "The prevalence of oral lesions in HIV-infected homosexual and bisexual men: three San Francisco epidemiological cohorts." AIDS 1991;5:519-25.
74	Maurer T.A & Berger T.G. "Dermatologic manifestations of HIV infection" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05derm/index.html, March 1998.
75	Koehler J.E., Quinn F.D., Berger T.G., et al. "Isolation of Rochalimaea species from cutaneous and osseous lesions of bacillary angiomatosis." N Engl J Med 1992;327:1625-1631.
76	McGuire D. & So Y.T. "The nervous system in HIV and AIDS" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05neuro/index.html, June 1998.
77	Levy R.M., Bredesen D.E. & Rosenblum M.L. "Neurological manifestations of the acquired immunodeficiency syndrome (AIDS): Experience at UCSF and review of the literature." J Neurosurg 1985;62:475-95.
78	Gendelman H.E., Lipton S.A., Epstein L., et al. "The Neurology of AIDS." New York: Chapman & Hall, 1998.
79	Navia B., Jordan B. & Price R. "The AIDS dementia complex. I. Clinical Features." Ann Neurol 1986;19:517-524.
80	Huang L. "The evaluation of repiratory symptoms in HIV-infected patients" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05pulm/index.html, May 1998.
81	Cheitlin M.D. "Cardiac involvement in HIV disease" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05card/index.html, February 1998.
82	Heidenreich P.A., Eisenberg M..J, Kee L.L., et al. "Pericardial effusion in AIDS. Incidence and survival." Circulation 1995;92:3229-3234.
83	Hellerstein M.K. "Endocrine abnormalities" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05endo/index.html, February 1998.
84	Northfelt D.W. "Hematological aspects of HIV infection" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05heme/index.html, February 1998.
85	Rodriguez R.A., Schoenfeld P. "Renal manifestations of HIV infection" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05renal/index.html, July1998.
86	Winston J, Klotman P. Are we missing an epidemic of HIV-associated nephropathy. J Am Soc Nephrol 1996;7:1-7.
87	Koch J., Kim L.S. & Friedman S. "Gastrointestinal manifestations of HIV infection" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05gi/index.html, June1998.
88	Ahmed I., Ai E., Luckie A. "Ophthalmic manifestations of HIV infection" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05eye/index.html, March 1998.
89	Lee K.C., Tami A.A. "Ottolaryngologic manifestations of HIV infection" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/05ent/index.html, August 1998.
90	Katz M.H. "Epidemiology of HIV-Related Cancers " The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/07malepi/index.html, November 1998.
91	Degtyarenko K.N. "Structural domains of P450-containing monooxygenase systems." Protein Engineering vol 8 no. 8 pp. 737-747, 1995.
92	Vercruysse  A. "Toxicologie." Cursus 2de graad apotheker VUB 1997;pp.17.
93	Buck M.L. "The cytochrome P450 enzyme system and its effect on drug metabolism" Pediatric Pharmacotherapy 1997;3(5).
94	Meyer J.M. &Rodvold K.A. "Drug biotransformation by the cytochrome P-450 enzyme system" Infect Med 1996;13(6):452,459,463-464,523.
95	Kolars J.C.,Lown K.S., Schmielin-Ren P., Ghosh M., Fang C. "CYP3A4 gene expression in gut epithelium" Pharmacogenetics. 1994;4:247-59.
96	Wrighton S.A., Ring B.J., Watkins P.B. & Vandenbranden M. "Identification of a polymorphically expressed member of the human cytochrome P-450III family." mol Pharmacol. 1989;36:97-105.
97	Smith, G.C., Tew, D.G. & Wolf, C.R. "Dissection of NADPH-cytochrome P450 oxidoreductase into distinct functional domains." Proc. Natl. Acad. Sci. USA 1994;91, 8710-8714.
98	Poulsen H.E. & Loft S. "The impact of genetic polymorphisms in risk assessment of drugs." Arch Toxicol Suppl 1992;16:211-222.
99	Dossing M., Pilsgaard H., Rasmussen B. & Poulsen H.E. "Time course of phenobarbital and cimetidine mediated changes in hepatic drug metabolism." Eur J Clin Pharmacol. 1983;25:215-22.
100	Jones R.S. & Gelone S.P. "Antiretroviral Drugs to Fight AIDS" Hospital Medicine 1997;33(8): 31-33, 37-38, 40-42, 45.
101	Collins C. & Coates T.J. "Outside the Prevention Vacuum: Issues in HIV Prevention for Youth in the next Decade" the Aids Reader 1997;7(5):149-154.
102	Kubic M. "New Ways to Prevent and Treat AIDS" FDA Consumer January-February 1997.
103	Gerberding J.L. "Transmission of HIV to Health Care Workers" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/01hcw/index.html, February 1998.
104	Gerberding J.L. "Management of occupational exposures to blood-bone viruses" N Engl J Med 1995;332:444-451.
105	Johnson R.P. & Kalams S. "AIDS Vaccines" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/03vacc/index.html, May 1998.
106	Deeks  S.G. & Volberding P. "Antiretroviral Therapy for HIV Disease" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/04arvrx/index.html, August 1998.
107	Yarchoan R. "Antiviral Therapy: In Search of the Optimum Combination." The AIDS Reader 1996;6(2):47-53,57.
108	Sepkowitz KA. "Effect of HAART on natural history of AIDS-related opportunistic disorders." Lancet 1998;351(9098):228-230.
109	Fatkenheuer G., Theisen A., Rockstroh J., et al. "Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients." AIDS 1997;11(14):F113-F116.
110	Flexner C. "Drug therapy: HIV-protease inhibitors." N Engl J Med 1998;338:1281-1292.
111	Colemann R.L. & Holtzer C. "HIV-Related Drug Information" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/04regime/index.html, August 1998.
112	Visnegarwala F., Krause K.L. & Musher D.M. "Severe diabetes associated with protease inhibitor therapy." Ann Intern Med 1997;127:947.
113	Nelfinavir (Viracept) package insert (1997); Agouron Pharmaceuticals, La Jolla CA.
114	Lee B.L. "Drug Interactions and Toxicities in Patients with HIV Disease" The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/04tox/index.html, August 1998.
115	Eastone JA & Decker, DF. "New-onset diabetes mellitus associated with use of protease inhibitor." Ann Intern Med 1997;127:948.
116	Indinavir (Crixivan) package insert (1997); Merck, West Point PA.
117	Norvir (Ritonavir), Abbott Laboratories, Ritonavir Formulary Kit, January 1996.
118	Saquinavir (Invirase) package insert (1997); Roche Laboratories, Nutley NJ.
119	Dobkin J.F. "AIDS Bulletin. Abacavir Enters the Clinic." Infect Med 16(1):7,1999..
120	Carpenter C.C.J., Fischl M.A., Hammer S.M., et al. "Antiretroviral therapy for HIV infection in 1996: recommendations of an international panel." JAMA 1996;276:146.
121	Hartman N.R., et al. "Pharmacokinetics of 2', 3'-dideoxyadenosine and 2', 3'-dideoxyinosine in patients with severe human immunodeficiency virus infection." Clin Pharmacol Ther 1990;47:647-654.
122	Kahn J.O., Lagakos S.W., Richman D.D., et al. "A controlled trial comparing continued zidovudine with didanosine in human immunodeficiency virus infection." N Engl J Med 1992;327:581-587.
123	Epivir (Lamivudine), Glaxo Wellcome, Package Insert, January 1996.
124	Spruance S.L., Pavia A.T., Mellors J.W., et al. "Clinical efficacy of monotherapy with stavudine compared with zidovudine in HIV-infected, zidovudine experienced patients". Ann Intern Med 1997;126:355-363.
125	Zerit (Stavudine), Bristol-Myers Squibb, Package Insert, July 1994.
126	Abrams D.I., Goldman A.I., Launer C., et al. "A comparative trial of didanosine or zalcitabine after treatment with zidovudine in patients with human immunodeficiency virus infection." N Engl J Med 1994;330:657-662.
127	Hochster H., Dieterich D., Bozzette S., et al. "Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS: An AIDS Clinical Trials Group study." Ann Intern Med 1990;113:111-117.
128	Dobkin J.F. "AIDS Bulletin. Efavirenz Receives FDA Approval." Infect Med 1998;15(11):747.
129	Foster R.H. & co. "Abacavir." Drugs 1998;55,5:729-736.
130	Adkins & co. "Amprenavir" Drugs 1998;55,5:729-736.
131	HIV Research Group. "Interaction Charts." http://www.liv.ac.uk/hivgroup
132	"Potential intreactions amongst antiretroviral agents used to treat HIV infection." Departement of Pharmacology & Therapeutics, University of Liverpool.
133	Coleman R.L. & Holtzer C. "HIV-Related Drug Information." The AIDS knowledge base http://hivinsite.ucsf.edu/akb/1997/04regime/index.html, August 1998.
134	"Consensus Statement: Antiretroviral Therapy for HIV Infection in 1998. Updated Recommendations of the International AIDS Society-USA Panel." JAMA 1998;280,178-84.
135	Database Pharmacia-Upjohn: HIV Drug Interactions Fact Sheet. Drug Interactions Search Report Created On 1/10/1998
136	MC Donald C.K. "Avoiding drug interactions with antiretroviral agents (partI)." The Journal of Respitory Diseases. 1998;19,1:24,35.
137	Burger D.M. "Klinisch relevante interacties met andere anti-HIV-middelen." Pharm.Weekbl. 1998;133,6,280-283.
138	Taburet A.M. & co. "Drug interactions with Antiviral Drugs." Clin. Pharmaco. 1996;30,5:385-401.
139	Perry C.M. & Balfour J.A. "Didanosine An Update on its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy in the Management of HIV Disease." Drugs. 1996;52,6:928-962.
140	Ferry J.J. & co. "Pharmacokinetic Drug-Drug Interaction Study Of Delaviridine and Indinavirin Healhy Volunteers." Journal of AIDS and Human Retrovirology. 1998;18:252-259.
141	Burger D.M. "Klinisch relevante geneesmiddelinteracties met andere antiretrovirale geneesmiddelen." Pharm.Weekbl. 1996;131,43,1232-1234.
142	Jarvis B. and co. "Nelfinavir. A review of its Therapeutic Effcacy in HIV Infection." Drugs 1998;56,1:147-167.
143	"Geneesmiddelprofiel: Nelfinavir (Viracept®)" P.W. 1998;133,38-:1446-1451.
144	Perry M.P. & Faulds D. "Lamivudine An Update on its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy in the Management of HIV Disease." Drugs. 1997;53,4:657-680.
145	Murphy R.L. & co. "Drug Evaluation. Anti-infectives. Nevirapine: a review of its development, pharmacological profile and potential for clinical use." Exp. Invest. Drugs. 1996;5(9),1183-1199.
146	Mac Dougall D.S. "Update on Nevirapine: Quest for an niche. Combination therapy with nevirapine may be a useful option for some HIV-infected persons. This NNRTI may fill certain roles still unmet by currently available antiretroviral agents." Journal of the association of Physicians in AIDS Care 1997,sept:37-43.
147	Hansten P.D. & co. "Drug Interaction Newsletter. AClinical Perspective and Analysis of Current Developments." Drug Interactions and Updates Quaterly. 1996;30,5:385-401.
148	Lea A.P. & Balfour J.A. "Didansine." Drugs 1996;52,4:541-546.
149	Lea A.P. & Faulds D. "Stavudine A Review of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Potential in HIV Infection." Drugs. 1996;51,5:846-864.
150	Wiltink  H.H. & co. "Zalcitabine (Hivid®)." P.W. 1995;130,1:16-20.
151	Burger D.M. & co. "Didanosine (Videx®)." P.W. 1993;128,29:838-842.
152	Adkins J.C. & co. "Zalcitabine. An Update of its Pharmacodynamic and Pharmacokinetic Properties and Clinical Efficacy in the Management of HIV Infection." Drugs. 1997;53,6:1054-1080.
153	Burger D.M. & co. "Bioanalyse and clinical pharmacokinetics of antiretroviral agents in HIV-infected individuals." Pharmacy World & Science 1995;17,6:266-272.
154	Wilde M.L. & Langrtry H.D. "Zidovudine. An Update of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Efficacy." Drugs. 1993;46,3:515-578.
155	Adkins J.C. & Noble S. "Efavirenz." Drugs. 1998;56,6:1055-1064.
156	Burger D.M. "Antiretrovirale geneesmiddelen in de pijplijn." Pharm.Weekbl. 1998;133,6:273-279.
157	Burger D.M. & co. "Internationale indrukken over combinaties en effecten van aidsremmers." P.W. 1998;133,14:582-585.
158	Perry C.M. & co. "Saquinavir. Soft Gel Capsule Formulation. A review of its Use in Patients with HIV infection." Drugs 1998;55,3:461-486
159	Burger D.M. & co. "Lamivudine (Epivir®)." P.W. 1997;132,15:476-480.
160	Broekhuizen A. "Aidsbehandeling vraagt om maatwerk." P.W. 1998;133,6:256-259.
161	Burger D.M. & co. "De HIV-proteaseremmers: Ritonavir (Norvir®), Saquinavir (Invirase®),Indinavir (Crixivan®)." P.W. 1998;133,6:266-272
162	Hoetelmans & co. "HIV-proteaseremmers. De ontwikkeling van middelen die het enzym protease van HIV remmen, is een staaltje hoogwaardig'computer-aided drug design'" P.W. 1998;133,4:187-189.
163	Back D. & co. "Key issues in treatment failure. Interactions between antiretrovirals." AIDS. 1998;12,suppl 4:S6, PL 6.1.
164	Van Hees wijk R.P.G. & co. "Geneesmiddlprofiel Stavudine (Zerit®)." P.W. 1998;132,51/52;1938-1944.
165	Burger D.M. & co. "Farmacokinetisch onderzoek van zidovudine en enkele andere geneesmiddelen bij HIV-geïnfecteerden." P.W. 1993;128,11:345-351.

---